Search

Bradley R Garman

from Glenside, PA
Get Report
Related to:
Kathleen A Collina, 86Philip H Ciarrocchi, 91Cynthia M Dauscher, 64Kathleen Collina, 61
Connected to:
Andrew C Garman, 45Ashley R Garman, 38Bradley N Garman, 70Christy H Garman, 64Dale W Garman, 63Damien Q Garman, 45Darryl W Garman, 66Deette Garman, 40Duane T Garman, 55Flynn Garman, 54

Bradley Garman Phones & Addresses

  • 539 Abington Ave, Glenside, PA 19038

Resumes

Resumes

Bradley Garman Photo 1

Research Scientist, Late Clinical Development, Solid Tumor Translational Development Disease Team

View page
Location:
Glenside, PA
Industry:
Pharmaceuticals
Work:
GlaxoSmithKline Research & Development - Upper Providence Site (Collegeville, PA) since Feb 2013
DNA Sequencing Co-op
Kimmel Cancer Center - Thomas Jefferson University (Philadelphia, PA) May 2012 - Feb 2013
Flow Cytometry Research Technician
USDA-ARS - Eastern Regional Research Center (Wyndmoor, PA) Jun 2010 - Aug 2011
Biological Science Laboratory Technician
Education:
Thomas Jefferson University Graduate School of Biomedical Sciences 2011 - 2014
M.S. in Microbiology, Microbiology Research/Biotechnology track Ursinus College 2006 - 2010
B.S., Biology
Skills:
Cancer Genetics
Sequencing
Qpcr
Rt Pcr
High Throughput Ngs Sequencing
Laboratory
Sanger Sequencing
Primer Design
Bioinformatic Data Analysis
Multi Color Flow Cytometry
Sds Page
Fluorescene Activated Cell Sorting
Laboratory Management
Project Management
Nucleic Acid Extraction
Fluorescence Spectroscopy
Uv Spectroscopy
Agarose Gel Electrophoresis
Aseptic Cell Culture
Nautilus Lims Software
Graphpad Prism
Facs Diva
Microsoft Excel
Flowjo
Microsoft Powerpoint
Nexus 7.5
R Programming
Adobe Illustrator
Western Blot
Protein Extraction and Quantification
Interests:
Listening To Music
Cooking
Jogging
Community Service
Civil Rights and Social Action
Politics
Human Rights
Reading
Hiking
Sports
Science and Technology
Swimming
Health
Awards:
Spot Award
USDA - ARS
"Spot award is a form of an extra effort award that grants immediate recognition to individuals or groups of employees for their day-to-day extra efforts and contributions". http://www.ocio.usda.gov/directives/doc/DR4040-451-1.htm
GC550: Foundations in Biomedical Sciences Guest Lecturer
Thomas Jefferson University Graduate School of Biomedical Sciences
Gave a lecture on the principles of flow cytometry for a course taken by all first-year Ph.D. students at Thomas Jefferson University Graduate School of Biomedical Sciences.
Bradley Garman Photo 2

Bradley Garman

View page
Bradley Garman Photo 3

Bradley Garman

View page

Publications

Us Patents

Cancer Vaccines Targeting Boris And Uses Thereof

View page
US Patent:
20210401958, Dec 30, 2021
Filed:
Sep 20, 2021
Appl. No.:
17/479142
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.

Cancer Vaccines Targeting Mesothelin And Uses Thereof

View page
US Patent:
20210401959, Dec 30, 2021
Filed:
Sep 7, 2021
Appl. No.:
17/467728
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
A61K 39/39
A61P 35/00
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.

Cancer Vaccines Targeting Survivin And Uses Thereof

View page
US Patent:
20190175707, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219520
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
C12N 15/62
C12N 15/52
A61P 35/00
A61K 39/39
C07K 16/40
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.

Cancer Vaccines Targeting Muc16 And Uses Thereof

View page
US Patent:
20190175708, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219460
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
C07K 14/47
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.

Cancer Vaccines Targeting Boris And Uses Thereof

View page
US Patent:
20190175710, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219268
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.

Cancer Vaccines Targeting Mesothelin And Uses Thereof

View page
US Patent:
20190175711, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219287
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
A61P 35/00
A61K 39/39
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.

Cancer Vaccines Targeting Lemd1 And Uses Thereof

View page
US Patent:
20190175712, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219446
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
C07K 14/47
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.

Cancer Vaccines Targeting Prame And Uses Thereof

View page
US Patent:
20190175713, Jun 13, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219356
Inventors:
- Plymouth Meeting PA, US
Anna SLAGER - Lansdale PA, US
Bradley GARMAN - Glenside PA, US
Neil COOCH - Oreland PA, US
International Classification:
A61K 39/00
C12N 15/62
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.
Control profile
Bradley R Garman from Glenside, PA Get Report